FML Forte is a brand name for a topical ophthalmic suspension containing fluorometholone, a synthetic corticosteroid used to treat steroid-responsive inflammatory conditions of the eye. It is commonly prescribed for allergic conjunctivitis, keratitis, iritis, and other non-infectious inflammatory disorders of the cornea, conjunctiva, and anterior uvea. The drug is available as a 0.25% suspension, which is a higher concentration than standard fluorometholone (0.1%), providing a more potent anti-inflammatory effect while still aiming to minimize intraocular pressure (IOP) elevation compared to stronger corticosteroids.
Mechanism of Action
Fluorometholone acts by binding to glucocorticoid receptors, which then modulate gene expression leading to inhibition of phospholipase A2 and subsequent reduction of pro-inflammatory mediators such as prostaglandins and leukotrienes. This decreases capillary dilation, leukocyte migration, and fibroblast proliferation. The 0.25% formulation delivers a higher local concentration, enhancing its efficacy in moderate to severe ocular inflammation.
Indications
FML Forte is indicated for steroid-responsive inflammatory conditions of the eye, including allergic conjunctivitis, vernal keratoconjunctivitis, corneal abrasions with inflammation, herpes zoster keratitis (without epithelial involvement), iridocyclitis, and other forms of anterior uveitis. It is also used post-operatively to control inflammation after cataract or refractive surgery. However, it should not be used in patients with epithelial herpes simplex keratitis (dendritic keratitis), fungal infections, or untreated bacterial infections.
Dosage and Administration
The typical dosage is one to two drops instilled into the conjunctival sac every two to four hours during the initial 24–48 hours, then tapered to four times daily as inflammation subsides. In severe cases, the frequency may be increased. The bottle should be shaken well before use because it is a suspension. Patients should avoid touching the dropper tip to any surface to prevent contamination. Contact lenses should be removed before instillation and may be reinserted 15 minutes after administration.
Pharmacokinetics
Fluorometholone is poorly absorbed systemically due to rapid metabolism in the eye and liver. Its higher lipid solubility allows corneal penetration, but the 0.25% formulation does not significantly increase systemic side effects compared to the 0.1% version. Peak aqueous humor concentration occurs about 1–2 hours after instillation.
Efficacy
Clinical studies have shown FML Forte to be effective in reducing signs and symptoms of ocular inflammation, BautyFarmacia with a rapid onset of action. It is often chosen when a stronger anti-inflammatory effect is needed but with a lower risk of IOP elevation than dexamethasone or prednisolone acetate. However, it is not as potent as these agents, so it may not be sufficient for severe uveitis or post-operative inflammation in high-risk patients.
Safety and Tolerability
Common side effects include transient stinging, burning, blurred vision (from the suspension), and conjunctival hyperemia. Less common but serious adverse effects include cataracts (posterior subcapsular), secondary ocular infections (bacterial, fungal, viral), and glaucoma. The risk of IOP elevation is lower with fluorometholone than with other corticosteroids, but it still occurs, particularly in known steroid responders. Long-term use may also lead to corneal thinning and perforation in patients with corneal diseases.
Precautions and Contraindications
FML Forte is contraindicated in most viral diseases of the cornea and conjunctiva, including epithelial herpes simplex (dendritic keratitis), vaccinia, and varicella, as well as in fungal infections and untreated bacterial infections. It should be used with caution in patients with glaucoma or a history of steroid-induced IOP elevation. Intraocular pressure should be monitored regularly if therapy is prolonged (>10 days). The drug is pregnancy category C; use only if clearly needed. Nursing mothers should exercise caution. Pediatric safety has not been established for prolonged use.
Drug Interactions
No significant systemic interactions are known due to low absorption. However, concomitant use with other topical ophthalmic drugs may require a 5–10 minute interval between medications to avoid dilution.
Comparison with Other Corticosteroids
Compared to prednisolone acetate 1% (which is more potent), FML Forte has a better safety profile regarding IOP elevation but may be less effective for severe inflammation. It is often used as a step-down therapy or for mild-moderate conditions. Compared to loteprednol etabonate (a "soft steroid"), fluorometholone has a similar IOP risk profile but is slightly more potent.
Clinical Tips
- Always shake the bottle vigorously for about 10 seconds to ensure uniform suspension.
- Warn patients about temporary blurred vision and advise them not to drive until vision clears.
- Taper the dose gradually to avoid rebound inflammation.
- In patients with known steroid responders, consider alternative agents like NSAIDs or loteprednol.
FML Forte (fluorometholone 0.25%) is a valuable option in the ophthalmologist's arsenal for managing ocular inflammatory conditions. Its moderate potency and relatively low steroid-induced IOP elevation make it suitable for many clinical scenarios, particularly allergic and mild anterior uveitic conditions. However, it requires careful monitoring for IOP, cataract formation, and secondary infection. As with all corticosteroids, the lowest effective dose for the shortest duration should be used. Patient education on administration and potential signs of complications (pain, photophobia, visual changes) is essential. Future studies may further delineate its role in specific inflammatory eye diseases, especially in pediatric and steroid-sensitive populations.